Cyclerion Therapeutics, Inc.
CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, anā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.62
Price-4.02%
-$0.07
1Y
Price
Market Cap
$5.198m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1797.8%
EBITDA Margin-348.4%
Net Profit Margin-540.9%
Free Cash Flow MarginRevenue
$2.174m
+8.7%
1y CAGR-30.4%
3y CAGR-45.6%
5y CAGREarnings
-$1.946m
+36.3%
1y CAGR+57.9%
3y CAGR+47.3%
5y CAGREPS
-$0.75
+38.0%
1y CAGR+60.0%
3y CAGR+50.9%
5y CAGRBook Value
$8.570m
$9.370m
Assets$800k
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$2.827m
+34.8%
1y CAGR+54.0%
3y CAGR+37.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company